Key result
Qiliqiangxin attenuated adverse cardiac remodeling, improved heart function, and reduced myocardial fibrosis and apoptosis after myocardial infarction in ovariectomized mice via activation of PPARγ.
Why the study?
Does Qiliqiangxin attenuate adverse cardiac remodeling after myocardial infarction in ovariectomized mice?
Population
Eight-week old female C57BL/6 mice subjected to left anterior descending coronary artery ligation seven days…
Comparison
Oral administration of Qiliqiangxin (QLQX) vs Vehicle
Design
Preclinical
Follow-up
21 days
Authors
Loading...
Hypothesis-generating in estrogen-deficient MI models; leaves open clinical translation pending human trials.
Does Qiliqiangxin attenuate adverse cardiac remodeling after myocardial infarction in ovariectomized mice?
Qiliqiangxin attenuates pathological cardiac remodeling post-myocardial infarction in ovariectomized female mice via PPARγ activation, suggesting a potential therapeutic role for postmenopausal women with MI.
Shen et al. (2017) studied Myocardial infarction in ovariectomized mice. Qiliqiangxin (QLQX) vs. Vehicle was evaluated on Heart function, myocardial fibrosis, and apoptosis. Qiliqiangxin attenuated adverse cardiac remodeling, improved heart function, and reduced myocardial fibrosis and apoptosis after myocardial infarction in ovariectomized mice via activation of PPARγ.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: